Revenue (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 31, 2023 and April 1, 2022 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.


	Biotechnology		Life Sciences		Diagnostics		Environmental & Applied Solutions		Total
For the Three-Month Period Ended March 31, 2023:
Geographical region:
North America(a)	$	618	$	708	$	1,124	$	572	$	3,022
Western Europe	647		364		420		277		1,708
Other developed markets	79		128		117		29		353
High-growth markets(b)	520		509		715		340		2,084
Total	$	1,864	$	1,709	$	2,376	$	1,218	$	7,167

Revenue type:
Recurring	$	1,511	$	1,039	$	2,112	$	724	$	5,386
Nonrecurring	353		670		264		494		1,781
Total	$	1,864	$	1,709	$	2,376	$	1,218	$	7,167

For the Three-Month Period Ended April 1, 2022:
Geographical region:
North America(a)	$	782	$	738	$	1,306	$	528	$	3,354
Western Europe	707		328		524		269		1,828
Other developed markets	85		137		124		32		378
High-growth markets(b)	642		463		690		333		2,128
Total	$	2,216	$	1,666	$	2,644	$	1,162	$	7,688

Revenue type:
Recurring	$	1,801	$	1,037	$	2,370	$	690	$	5,898
Nonrecurring	415		629		274		472		1,790
Total	$	2,216	$	1,666	$	2,644	$	1,162	$	7,688

(a) The Company defines North America as the United States and Canada.

(b) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.